Toxicological study of a new doxorubicin-loaded pH-sensitive liposome : a preclinical approach.

dc.contributor.authorSilva, Juliana de Oliveira
dc.contributor.authorMiranda, Sued Eustaquio Mendes
dc.contributor.authorLeite, Elaine Amaral
dc.contributor.authorSabino, Adriano de Paula
dc.contributor.authorBorges, Karina Braga Gomes
dc.contributor.authorCardoso, Valbert Nascimento
dc.contributor.authorCassali, Geovanni Dantas
dc.contributor.authorGuimarães, Andrea Grabe
dc.contributor.authorOliveira, Mônica Cristina de
dc.contributor.authorBarros, André Luís Branco de
dc.date.accessioned2019-04-15T14:22:43Z
dc.date.available2019-04-15T14:22:43Z
dc.date.issued2018
dc.description.abstractDoxorubicin (DOX) is widely used in cancer treatment, however, the use of this drug is often limited due to its cardiotoxic side effects. In order to avoid these adverse effects, the encapsulation of DOX into nanosystems has been used in the last decades. In this context, pH-sensitive liposomes have been shown promising for delivering cytotoxic agents into tumor cells, however, the lack of information about in vivo toxicity of this nanocarrier has impaired translational studies. Therefore, the aim of this work was to investigate the acute toxicity and cardiotoxicity of DOX-loading pH-sensitive liposomes (SpHL-DOX). To achieve this, female BALB/c mice, after intravenous administration, were monitored by means of clinical, laboratory, histopathological and electrocardiographic (ECG) analyses. Results indicate that SpHL was able to prevent renal toxicity and the hepatic injury was less extensive than free DOX. In addition, lower body weight loss was associated with less ECG QT interval prolongation to animals receiving SpHL-DOX (14.6 ± 5.2%) compared to animals receiving free DOX (35.7 ± 4.0%) or non-pH-sensitive liposomes (nSpHL-DOX) (47.0 ± 9.8%). These results corroborate with SpHL-DOX biodistribution studies published by our group. In conclusion, the SpHL-DOX showed less toxic effects on mice compared to free DOX or nSpHL-DOX indicating that SpHL-DOX is a promising strategy to reduce the serious cardiotoxic effects of DOX.pt_BR
dc.identifier.citationSILVA, J. de O. et al. Toxicological study of a new doxorubicin-loaded pH-sensitive liposome : a preclinical approach. Toxicology and Applied Pharmacology, v. 352, p. 162-169, ago. 2018. Disponível em: <https://www.sciencedirect.com/science/article/pii/S0041008X18302564?via%3Dihub>. Acesso em: 25 fev. 2019.pt_BR
dc.identifier.issn0041008X
dc.identifier.urihttp://www.repositorio.ufop.br/handle/123456789/11014
dc.identifier.uri2https://www.sciencedirect.com/science/article/pii/S0041008X18302564pt_BR
dc.language.isoen_USpt_BR
dc.rightsrestritopt_BR
dc.subjectDoxorubicinpt_BR
dc.subjectAcute toxicitypt_BR
dc.subjectCardiotoxicitypt_BR
dc.subjectElectrocardiogrampt_BR
dc.titleToxicological study of a new doxorubicin-loaded pH-sensitive liposome : a preclinical approach.pt_BR
dc.typeArtigo publicado em periodicopt_BR
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ARTIGO_ToxicologicalStudyNew.pdf
Size:
2.08 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
924 B
Format:
Item-specific license agreed upon to submission
Description: